New drug MDI-2517 put to the test in first human safety trial
Knowledge-focused
Completed
This early-stage trial tested the safety of a new drug called MDI-2517 in 32 healthy adults aged 18 to 55. Participants received either a single or multiple doses of the drug or a placebo. Researchers monitored side effects, lab results, vital signs, and how the drug moves throug…
Phase: PHASE1 • Sponsor: MDI Therapeutics, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:37 UTC